Hemodialysis Vascular Grafts Market By Raw Material (Polyurethane, Polyester, Polytetrafluoroethylene and Biological Material) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The market for hemodialysis vascular grafts is expected to grow from US$ 196.6 million in 2017 to US$ 285.2 million by 2026, representing balanced growth at a compounded annual growth rate (CAGR) of 4.3% from 2018 to 2026. Atrial fibrillation is the most common type of cardiac arrhythmia diagnosed globally. According to the research findings brought forward by the World Health Organization (WHO), the number of end-stage renal disease patients worldwide receiving dialysis will be approximately 5.24 million by 2030. The common causes associated with morbidity during hemodialysis are infection, hemorrhage, and vascular graft rejection. Synthetic materials are made with a blend of polymers to achieve the desired strengths, adhesion, durability, and pliability. Bioengineered materials will be the latest trendsetter due to the advantages associated with them, such as negligible graft rejection and excellent biocompatibility.

Market Synopsis

Excellent adhesion, native fistula pliability, and reimbursement scenarios drive the polytetrafluoroethylene raw material market's growth.

Polytetrafluoroethylene is leading the raw material segment for hemodialysis vascular grafts. The primary features that are responsible for the dominance of polytetrafluoroethylene as a vascular graft are its outstanding adhesion properties, native fistula pliability, and reimbursement scenario. High dielectric strength and a low coefficient of friction ensure a smooth and painless hemodialysis procedure in patients suffering from chronic kidney disease. Polyurethane holds the second largest market owing to positive attributes such as its material strength and ability to provide a thinner inner wall as a vascular graft, thereby providing a larger inner luminal diameter to provide excellent blood flow during hemodialysis procedures. Biological raw materials will be the fastest-growing segment during the forecast period owing to their low infection rate, low hemorrhage, and excellent biocompatibility. They are made from human saphenous veins and other bioengineered materials.

The growing geriatric population suffering from chronic kidney disease, as well as rising healthcare costs, are driving market growth in North America.

North America is presently holding 36% of the regional segment of the hemodialysis vascular grafts market. As per the research study conducted by the Centers for Disease Control and Prevention (CDC) in 2016, approximately 4.9 million United States citizens were reported to have been diagnosed with kidney disease. Rising healthcare expenditures and a growing geriatric population suffering from chronic kidney disease are driving market growth in the North American region. The existence of major players such as C.R. Bard, Inc., Terumo Medical Corporation, and W.L. Gore & Associates, Inc., etc. further propel the market's growth in the North American region. Europe holds the second-largest market with a 28% share, owing to the supportive regulatory environment provided by the European Medical Agency (EMA) and the increasing demand for hemodialysis in comparison to peritoneal dialysis. Asia Pacific represents a 20% market share and is expected to register excellent growth in the near future on account of the increasing prevalence of renal disorders and proactive government policies to counteract kidney complications.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is segmented by raw materials and by geography.

Pharmaceutical companies manufacturing hemodialysis vascular grafts are C.R. Bard, Inc., CryoLife, Inc., Getinge AB, InnAVasc Medical, Inc., LeMaitre Vascular, Inc., Merit Medical Systems, Inc., Proteon Therapeutics, Inc., Terumo Medical Corporation, Vascular Genesis, and W.L. Gore Associates.

Key questions are answered in this report.

  • What are the latest market trends prevalent in the hemodialysis vascular grafts market?
  • What will be the market size and CAGR during the forecast period from 2018 to 2026?
  • What is hemodialysis, and what are its benefits for patients suffering from end-stage renal disease?
  • Which pharmaceutical companies are engaged in the production of hemodialysis vascular grafts?
  • What are the advantages associated with raw materials such as polytetrafluoroethylene and polyurethane?
  • Why is North America the largest regional segment in the hemodialysis vascular grafts market?

Frequently Asked Questions:

The market for Hemodialysis Vascular Grafts is expected to reach US$ 285.2 Mn 2026

The Hemodialysis Vascular Grafts market is expected to see significant CAGR growth over the coming years, at 4.3%.

The report is forecasted from 2018-2026

The base year of this report is 2017.

C.R.Bard, Inc.,CryoLife, Inc.,Getinge AB.,InnAVasc Medical, Inc.,LeMaitre Vascular, Inc. are some of the major players in the global market

Choose License Type
Trusted By
Published Date:  Feb 2019
Category:  Medical Devices
Report ID:   59569
Report Format:   PDF
Pages:   120
Rating:    4.2 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support